In early February, Behavioral Innovations, a Dallas-based Applied Behavior Analysis provider, announced a partnership with CareCredit, the Synchrony-owned health and wellness credit card that has become a fixture in dental offices, veterinary clinics, and medical spas across the country. The arrangement marks the first time a major ABA provider has offered CareCredit as a payment option for therapy services. Behavioral Innovations is also expanding its own internal payment plans to include a 24-month option, giving families two new avenues to finance the portion of care that insurance does not cover.

The announcement was modest in presentation. A press release, a quote from the company’s chief operating officer about “removing barriers to care,” a link to the company’s website. But the underlying signal is harder to dismiss. CareCredit built its business on elective, cash-pay procedures. Botox, teeth whitening, LASIK. Its arrival in ABA, a service that is mandated for coverage under most state insurance laws and required as an essential health benefit under the Affordable Care Act, is not so easy to wave away.

As a business decision, the partnership is defensible. What it reveals, however, is something much more troubling for the ABA industry: a coverage gap so wide it now requires its own line of credit. How this gap transpired involves a mixed bag of compliance law, provider economics, and the subtle distortion that financial pressure exerts on clinical decisions.

The Behavioral Innovations announcement did not arrive in isolation. Kris Gochenour, Chief Financial Officer at Verbal Beginnings, an ABA provider in Maryland, has been working toward the same decision since last October. Before approving a provider, CareCredit conducts on-site visits to verify that its financing will be used for clinical services, and for Verbal Beginnings that process has been more complicated for home-based care than for its clinic programs. “They want to be able to validate what they’re underwriting,” Gochenour said. “When you’re delivering therapy in someone’s living room, that’s harder to prove. The verification process for home and community-based services requires a different approach than clinic-based programs, and CareCredit has been thorough about getting that right.” The caution is not arbitrary: CareCredit’s experience with fraud in other healthcare settings has made it attentive to where its credit actually flows. That two providers of meaningfully different size, operating in different markets, arrived at the same solution in the same season is itself a signal worth reading.

Skin in the Game

To understand why a company like Behavioral Innovations would turn to consumer financing, it helps to understand the compliance problem that ABA providers face every day.

American health insurance operates on a principle called patient financial responsibility: the idea that insured individuals should share some portion of the cost of their care through copays, coinsurance, and deductibles. The mechanism is designed as a utilization control, a small financial stake that, in theory, discourages unnecessary consumption of services. For most healthcare encounters, it functions as intended. A $30 copay for an office visit is a manageable friction point. But ABA therapy is not most healthcare encounters. Treatment is intensive, often spanning 20 to 40 hours per week over months or years. Even modest cost-sharing percentages, applied to that volume, can produce bills that overwhelm a family’s budget.

Harry Nelson, a healthcare attorney and chair of the Healthcare Practice Group at Leech Tishman who has spent three decades advising behavioral health providers on regulatory and compliance matters, described the bind in blunt terms during a conversation with Acuity Media Network at the 2026 BHASe Summit in Miami. “You’re dealing with parents who are financially just exhausted because of all the care and support and intervention resources that they need,” he said. “You have this population that’s totally depleted financially when they’re coming into the process.”

The problem intensifies when providers try to help. Waiving a copay or offering a discount might seem like a compassionate response, but it carries serious legal risk. Insurance companies interpret the routine waiver of patient financial responsibility as a form of fraud, on the theory that if a provider never intended to collect the patient’s share, the billed amount was inflated to begin with. Nelson noted that this was not always the case. “Twenty-five years ago, nobody ever cared about it,” he said. But as behavioral health became an essential health benefit under the ACA, and insurance companies assumed larger obligations for these services, enforcement tightened. Providers who fail to collect copays now risk payer audits, recoupment demands, and accusations of fraudulent billing.

The alternative, offering financial hardship waivers, is equally fraught. While hospitals have long used financial hardship programs to discount care for uninsured or underinsured patients, those programs were designed for a specific context: a relatively small share of a hospital’s patient population, with modest discounts, robust verification processes, and clear legal frameworks developed over decades. Some states, including Florida, go further and ban financial hardship waivers and discounts in healthcare settings outside of hospitals entirely. The legal framework for such programs in outpatient behavioral health is thin and varies dramatically by state. Nelson described it as “very treacherous waters,” and the reason, he explained, is that behavioral health presents a categorically different problem. In a hospital, financial hardship programs might apply to a small fraction of patients. In an ABA practice, it is often the vast majority of families who cannot afford some or all of their share of cost. Payers object not only to the breadth of those discounts, but to the absence of the robust verification, reasonable standards, and consistent practices that give hospital hardship programs their legal footing. Many ABA providers, Nelson suspects, rely on financial hardship waivers without fully appreciating how exposed that leaves them. “That is a really legally risky strategy,” he said.

A Clean Paper Trail

Nelson was careful to distinguish between the provider calculus and the family one. From the provider side, CareCredit is a low-risk solution to a high-risk problem. It addresses the compliance exposure, keeps the revenue cycle clean, and removes a barrier that might otherwise prevent families from initiating services. If a provider has 100 interested families and only 50 can afford their out-of-pocket share, financing closes the gap without requiring the provider to absorb the cost or gamble on hardship waivers.

From the family side, the picture is more complicated. CareCredit is, at its core, a credit card. Its standard annual percentage rate for new accounts is 32.99%, with a penalty rate of 39.99% that can be applied to accounts with repeated missed payments. While the product offers deferred-interest promotional periods of six to twenty-four months, families who fail to pay the full balance before the promotional window closes are charged interest retroactively from the date of the original purchase at the full rate.

The families most likely to need it are, by Nelson’s description, already financially depleted. Adding consumer debt on top of the existing burden of caring for a child with autism is not a neutral proposition. “It could, there could be some really terrible stories that come out of this dependence on what is essentially credit card debt from CareCredit,” Nelson said. He summarized the tension succinctly: “I think it’s smart from the provider side, but dangerous from the patient side.”

On Paper, and in Practice

The premise of CareCredit’s entry into ABA rests on a gap that, by the logic of existing law, should not be as wide as it appears to be. Every state in the country has some form of autism insurance mandate, and the ACA requires that behavioral health services be covered as an essential benefit. Medicaid, which covers a significant share of children receiving ABA, is supposed to ensure access regardless of a family’s ability to pay. On paper, the coverage infrastructure is extensive. In practice, the gap between statutory obligation and lived experience is where the story gets more complicated.

The sources of out-of-pocket exposure are varied and often cumulative. Families with commercial insurance may face high-deductible plans that require thousands of dollars in spending before coverage begins. Coinsurance obligations of 10% to 20% on a therapy that runs $120 to $150 per hour, delivered 20 or more hours a week, can produce monthly bills that rival a mortgage payment. Out-of-network situations, which arise when a family’s preferred provider does not participate in their plan’s network, can leave families responsible for the balance between what the provider charges and what the insurer deems reasonable. And prior authorization denials, which require families and providers to navigate an appeals process before services are approved, can create gaps in care during which families are either paying out of pocket or going without.

Keeping Families in the Chair

For providers, the CareCredit partnership represents one answer to a question that has been building for years: how to keep families in treatment when the financial burden of cost-sharing threatens to push them out.

For Gochenour, the case for CareCredit is grounded in what he has watched happen to families over the past three or four years. The cost burden has not been stable. Co-pays keep rising. Many marketplace plans carry premiums that exceed the deductibles they are supposed to offset. ABA compounds the problem because it rarely exists in isolation: children who need it often also require speech therapy, occupational therapy, or other services, each with its own deductible exposure. “We’ve seen a growing number of families where out-of-pocket costs are becoming a barrier to consistent treatment,” he said. “If out-of-pocket costs keep climbing the way they have, the industry is going to have an access problem it can’t solve one family at a time.” From the provider side, the product’s non-recourse structure adds a further incentive: unlike internal payment plans, where unpaid balances become the provider’s collection problem, CareCredit transfers that risk to the financing company, giving smaller operators a cleaner path through the receivables cycle. For practices that have been absorbing bad debt while families struggle to catch up, that is not a minor consideration.

Still, Gochenour was careful to draw a line between a useful tool and a well-used one. CareCredit’s value, in his view, hinges entirely on whether the family holding the card understands what they have signed up for. “It’s a credit card at the end of the day,” he said. “If the consumer isn’t educated on how to use it, balances can grow quickly.” The card’s usability across healthcare settings, from ABA providers to veterinary clinics, makes it a practical way to consolidate out-of-pocket spending across multiple providers into a single line of credit. But the same breadth that makes it convenient also makes it easy to lose track of. For smaller providers without the pricing leverage or operational scale that larger platforms can deploy, the partnership offers something beyond convenience: a measure of competitive parity. “It levels the playing field,” Gochenour said. “Providers of all sizes need tools that let them focus on care delivery rather than collections.”

The Invisible Variable

There is also a clinical dimension to the financing question that extends beyond the balance sheet. ABA therapy is not a commodity that families choose to purchase the way they might choose cosmetic dentistry. It is a medically necessary intervention for children whose developmental trajectory depends, in many cases, on early, intensive treatment. The introduction of a financing mechanism into that equation raises questions about whether financial considerations could begin to shape clinical decisions in ways that are difficult to detect and harder to reverse.

Gochenour articulated the provider’s aspiration plainly: finances should not get in the way of care. But the premise embedded in that statement, that a provider can cleanly separate a family’s financial situation from their clinical one, is more complicated in practice. When the ability to sustain treatment depends on a revolving line of credit, the credit limit becomes a de facto ceiling on how much therapy a child receives. A family that has exhausted their CareCredit balance, or that has missed enough payments to trigger the penalty rate, does not face a billing inconvenience. They face a decision about whether to continue treatment at all. Nelson had already described the families arriving at ABA providers as financially depleted before the first session begins. Adding a debt instrument to that picture does not resolve the underlying pressure. It defers it, and in deferring it, makes the eventual reckoning harder to absorb.

The concern is not that CareCredit itself distorts clinical judgment. The concern is that its presence in the ABA ecosystem reflects a set of financial pressures that already do. When a family cannot afford their copay, the provider faces a choice between absorbing the cost, risking a fraud allegation, or losing the patient. When a family takes on credit card debt to continue therapy, the debt itself becomes a variable in how long they can sustain treatment. The financing product does not create these pressures. But it does make them visible in a way that is difficult to look away from.

The Structural Tell

Behavioral Innovations has not disclosed how many families have enrolled in CareCredit since the partnership launched, nor has it provided detail on the terms of the financing arrangement beyond the availability of the product and the expansion of its internal payment plans. CareCredit’s standard terms vary by provider and promotional period, and the company offers a range of repayment options including deferred-interest plans that carry significant risk if not paid in full before the promotional window closes.

Whether other ABA providers follow suit will depend on several factors: the competitive pressure to match a rival’s payment flexibility, the legal and compliance guidance providers receive from their counsel, and, perhaps most importantly, whether the underlying reimbursement landscape shifts enough to make consumer financing unnecessary. If payers increase reimbursement rates, streamline authorization processes, and reduce the out-of-pocket burden on families, the market for CareCredit in ABA will shrink on its own. If they do not, the partnership announced in February may look, in retrospect, less like an innovation and more like an early indicator of a structural problem that the industry has been slow to name.

Nelson, the healthcare attorney, offered a framing that captures the duality at the center of this story. CareCredit is, for providers, a clean and legally defensible way to handle a problem that has no easy answers. For families, it is a new form of exposure in a system that was supposed to protect them from exactly that. Both things can be true at the same time. The question is which one the industry chooses to act on.